PT  - JOURNAL ARTICLE
AU  - Shpitzen, Shoshi
AU  - Rosen, Haim
AU  - Ben-Zvi, Ayal
AU  - Meir, Karen
AU  - Levin, Galina
AU  - Gudgold, Amichay
AU  - Ben Dor, Shifra
AU  - Haffner, Rebecca
AU  - Zwas, Donna R.
AU  - Leibowitz, David
AU  - Slaugenhaupt, Susan
AU  - Banin, Eyal
AU  - Mizrachi, Rotem
AU  - Obolensky, Alexey
AU  - Levine, Robert A
AU  - Gilon, Dan
AU  - Leitersdorf, Eran
AU  - Tessler, Idit
AU  - Reshef, Noga
AU  - Durst, Ronen
TI  - Characterization of LTBP2 mutation causing Mitral Valve Prolapse
AID  - 10.1101/2024.07.21.24302849
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.07.21.24302849
4099  - http://medrxiv.org/content/early/2024/07/24/2024.07.21.24302849.short
4100  - http://medrxiv.org/content/early/2024/07/24/2024.07.21.24302849.full
AB  - Background Mitral Valve Prolapse (MVP) is a prevalent valvular disorder linked to considerable morbidity and mortality, affecting approximately 2.4% of the general population. A prior genome association study linked LTBP2 to this trait. We report a knockout mouse with LTBP2 mutation demonstrating valve phenotype as well as a family with a novel mutation causing MVPMethods Exome sequencing and segregation analysis were conducted on a large pedigree to identify mutations associated with MVP. Using CRISPR-Cas9 technology, two strains of mice were generated: one with a complete knockout (KO) of the LTBP2 gene and another with a knock-in (KI) mutation corresponding to the putative causative mutation. Echocardiography and histological examinations of valves were performed in the KO and the KI at the age of 6 months. Optical coherence tomography (OCT) and histological examination of the eyes was done at the same time. mRNA qPCR analysis for TGFβ signaling targets (periostin/POSTN, RUNX2, and CTGF) in valve tissues was analysed.Results The LTBP2 rs117800773 V1506M mutation exhibited segregation with the MVP trait. LTBP2 KO mice had higher incidence of myxomatous changes by histology (7 of 9 of KO vs. 0 of 7 control animals, p=0.00186) and echocardiography (7 of 9 vs. 0 of 8, p=0.0011). LTBP2 Knock-in mice for the human mutation showed a significantly elevated myxomatous histological phenotype (8 of 8 vs. 0 of 9, p=0.00004) as well as by echocardiography (6 of 8 vs. 0 of 9, p=0.00123). KO mice demonstrated a significant increase in the depth of the anterior chamber as well as reduced visual acuity. LTBP2 KO mice demonstrated overexpression of both TGFβ signaling targets RUNX2 and periostin (P=0.0144 and P=0.001826, respectively).Conclusion Animal models of LTBP2 KO and KI recapitulate MVP phenotype indicating that LTBP2 mutations are indeed causing myxomatous degeneration. Further, LTBP2 rs117800773 V1506M segregated with MVP in a large pedigree. Our data indicate the importance of LTBP2 in normal mitral valve function and that mutations in the gene care causing myxomatous valve.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe paper was supported by BSF grant 2017265, and Hadassah Medical Center bridge grant in 2021.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Hadassah Hebrew University Hospital in Jerusalem IRB and the Israeli Ministry of Health committee for genetic studies (0464-10-HMO)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.Non-standard Abbreviations and AcronymsLTBP2Latent Transforming Growth Factor Beta Binding Protein 2MVPMitral Valve ProlapseKOKnockoutKIKnock-inWTwild type mRNA messenger RNAPCRpolymerase chain reaction qPCRQuantitative polymerase chain reactionRUNX2Runx family transcription factor 2ECMextra-cellular matrix gRNA guide RNACRISPRClustered Regularly Interspaced Short Palindromic Repeats sgRNA single guide RNASSCSequence scan for crisprssODNsingle-stranded oligodeoxynucleotidestracrRNAtrans-activating CRISPR RNAcrRNACRISPR RNAsIDTIntegrated DNA TechnologiesH&EHematoxylin and eosin stainingDAPI4’,6-diamidino-2-phenylindoleqRT-PCRReal-Time Quantitative Reverse Transcription PCRCTGFconnective tissue growth factorGAPDHglyceraldehyde-3-phosphate dehydrogenase protein familyMRmitral regurgitationGWASgenome-wide association studyLTBPsLatent Transforming Growth Factor Beta Binding ProteinsMFSMarfan syndromeFBN1Fibrillin1LAPlatency-associated peptideOCTOptical coherence tomography